Table 3. Risk of the First Recurrent Gout Flares and All-Cause Mortality by Initiation of Either SGLT2i or Active Comparators Among Patients With Gout and Type 2 Diabetes.
| Outcome | Treatment cohort | |
|---|---|---|
| SGLT2i (n = 1548) | Active comparators (n = 4383)a | |
| First recurrent gout flares | ||
| Event, No. | 135 | 628 |
| Weighted mean follow-up, y | 2.57 | 2.46 |
| Weighted rate of event per 1000 person-years | 32.4 | 41.2 |
| Weighted RD (95% CI) per 1000 person-years | −8.8 (−17.2 to −0.4) | 0 [Reference] |
| Age-, sex-, and entry year–adjusted HR (95% CI) | 0.78 (0.64 to 0.95) | 1 [Reference] |
| Weighted HR (95% CI) | 0.81 (0.65 to 0.98) | 1 [Reference] |
| All-cause mortality | ||
| Event, No. | 63 | 607 |
| Weighted mean follow-up, y | 2.76 | 2.70 |
| Weighted rate of event per 1000 person-years | 18.8 | 24.9 |
| Weighted RD (95% CI) per 1000 person-years | −6.1 (−10.6 to −1.6) | 0 [Reference] |
| Age-, sex-, and entry year–adjusted HR (95% CI) | 0.67 (0.51 to 0.89) | 1 [Reference] |
| Weighted HR (95% CI) | 0.71 (0.52 to 0.97) | 1 [Reference] |
Abbreviations: HR, hazard ratio; RD, rate difference; SGLT2i, sodium-glucose cotransporter-2 inhibitors.
a
Active comparators consist of dipeptidyl peptidase-4 inhibitors or glucagonlike peptide-1 receptor agonist.